> "Reverie Labs uses machine learning to scan public molecule research, modify and develop its own molecules, and license the drugs they create to big pharmaceutical companies. The startup claims it can sell molecule licenses for $100 million, and has already signed a milestone deal worth up to $87 million."

I wonder if this is really molecular innovation or does it result in derivative work from a machine learning algorithm pattern matching human successes.